Calling all lung cancer patients with an EGFR or HER2 Exon 20 mutation. I have recently enrolled on a clinical trial in the United States which has had some very promising results. There are very few options for those who have this mutation other than chemotherapy. (The majority of EGFR positive patients have Exon 19 and 21 mutations for which there are already targeted treatments available).
The drug is called Poziotinib and information about it can be found by following the link below which includes data presented at the 18th IASLC World Conference on Lung Cancer in Japan very recently.
investor.sppirx.com/release...
Additionally a webcast is available until 28th October in which Dr. John Heymach, the Principal Investigator, from MD Anderson Hospital in Houston, Texas, outlines the positive results from the clinical trial so far.
investor.sppirx.com/events.cfm
I accessed the trial with support from the US based Exon20 Group which is dedicated to expediting the development of exon 20-targeted drugs for the benefit of patients and the global oncology community.
Anyone looking for support regarding EGFR or HER2 Exon 20 is encouraged to contact marcia@exon20group.org for further details.
This news gives hope for those of us with this mutation.
NSCLC EDFR Migration Stage 4 LC at 37.
NSCLC, results of CHART
Kras gene mutation trials- stage 4 lung cancer 
Treatment for Advanced /METASTIC NSCLC
